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1. STUDY OBJECTIVES 
The purpose of this study is to characterize the overall efficacy, safety, and tolerability of 
eculizumab in GBS subjects. 
 
1.1. Primary Endpoint 
【Safety】 
Frequency and severity of incidence of AEs/SAEs after treatment with investigational product. 
【Efficacy】 
Proportion of subjects who reach a score of Hughes functional grade (FG) 2 or lower on the 
functional grading scale at Week 4 (Response Rate) 
 
1.2. Secondary Endpoint 
【Efficacy】 
1. Proportion of subjects with improvement of one or more scores on the Hughes functional 
grading scale at each visit from baseline 
2. Proportion of subjects who are able to walk unaided (FG 2 or lower) at each visit  
3. Duration required for improvement by at least one grade on the functional grading scale *1 
4. Proportion of subjects who reach FG 1 or 0 at Week 24  
5. Change in the FG score between peak disability score and the scores at each visit  
6. Proportion of subjects with a clinically relevant improvement in the R-ODS score. An increase 
in the R-ODS score (0-48) converted to the centile metric score (0-100) by at least six points at 
each visit 
7. Proportion of subjects with a clinically relevant improvement in ONLS. (a decrease in the 
ONLS score from baseline by at least 1 point) at each visit 
8. Proportion and frequency of subjects who require ventilatory support (FG 5) 
9. Duration of ventilatory support 
10. Occurrence of relapse during the trial *2 
11. Overall survival during the trial (OS) 
12. Change in grip strength at each visit from baseline 
13. Change in results of the manual muscle test (MMT) score at each visit from baseline 
14. Change in the rate and results of below measures on median and ulnar nerve conduction test 
parameters from baseline: CMAP amplitude, distal latency, motor nerve conduction velocity, F 
wave latency, SNAP amplitude, and sensory nerve conduction velocity 
15. Change in vital capacity and % vital capacity at each visit from baseline 
16. Proportion of patients who undergo readministration of IVIg 
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*1: Investigators will determine the duration required for improvement by at least one grade on the 
Hughes functional grading scale according to clinical assessments and the subject’s diary.  
*2: Investigators will assess the clear recurrence of GBS observed after four weeks from the onset of 
GBS with reference to the NINDS diagnosis criteria. Therapy dependent exacerbation is not 
included.  
 
2. GENERAL CONVENTIONS IN STATISTICAL ANALYSIS 
2.1. Interim Analysis 
No interim analysis will be performed in this trial. 
 
2.2. Data Monitoring Committee 
Data Monitoring Committee will be set up to ensure the safety of the trial subjects in accordance 
with a separate set of operating procedures.  
 
2.3. Handling of Missing Data  
Unless otherwise noted, dropouts or missing data will not be replaced with substituted values created 
by statistical imputation. 
 
2.4. Data Transformation 
In the case of changes in variables such as square roots or logarithms, its precise procedures will be 
described in the statistical analysis plan.  
 
2.5. Significance Level and Confidence Interval  
Unless otherwise noted, results from all analyses will be assessed against the significance level(α) 
of 0.05 and the confidence interval (CI) of 0.95 as a two-sided test. 
 
2.6. Multiplicity Adjustment 
Unless otherwise noted, statistical adjustments for multiplicity will not be performed in this trial. 
 
2.7. Subgroup Analysis 
 
Not applicable 
2.8. Data Processing Conventions 
Definitions of days and period 
 The number of days will be calculated by subtracting the beginning date from the final date and 
one day will be added afterwards.  
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Examples: 
 Days dosed: If dosing ends on the first day of administration, the dosing period will be 
counted as one day.  
 Days until the occurrence of an adverse event (AE): If an AE occurs on the day after the 
first day of administration, the period until the onset of the AE will be counted as two 
days. 
 Survival period: If death occurs on the day after the first day of administration, the 
survival period will be counted as two days. 
 
 The number of days will be calculated as follows: 
 One year: 365.25 days 
 One month: 30.4375 days 
 One week: 7 days 
 
 The number of days after the initial date or the number of days before an event will be 
described as follows: 
 The first date of administration is set as the initial date: day (1)  
The following days will be counted up one by one. 
 
 One day before the initial date is set as day (-1) 
     The following backward days will be counted down one by one. 
 
 
Handling of digits after the decimal point 
 For means, standard deviations, and medians, the values will be displayed with one more 
number of decimal places than those of allotted in the CRF. (The calculated results will be 
displayed with two more number of decimal places than those of allotted in the CRF and the 
last digit will be rounded to produce the values).  
 All percentages should be rounded to one decimal place and the results will be reported 
(e.g.12.3%). 
 When calculating means, standard deviations, and/or medians for statistical analysis, the 
numbers will not be rounded during the calculation and only after the final results are obtained. 
  
Confidence Interval (CI) for the incidence rate  
Confidence interval of the incidence proportion (or incidence percentage) and response proportion 
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(or response percentage) will be calculated by exact method based on F distribution.  
The number of population for analysis will be defined as N, and the number of patients who 
experienced events,or the number of responders to the treatment will be defined as X. The response 
rate (p) , the upper limits (pu), or lower limits (pL) of the confidence interval of 100 (1 – α)% at a 
two sided-test, will be calculated by the following equations. 95% confidence interval reflects α of 
0.05. 
 
𝑝𝑝 = 𝑋𝑋
𝑁𝑁
, 
𝑝𝑝𝑈𝑈 = �1 + 𝑁𝑁 − 𝑋𝑋(𝑋𝑋 + 1)𝐹𝐹 �1 − 𝛼𝛼2 , 2(𝑋𝑋 + 1),2(𝑁𝑁 − 𝑋𝑋)��
−1, 
𝑝𝑝𝐿𝐿 = �1 + 𝑁𝑁 − 𝑋𝑋 + 1
𝑋𝑋 𝐹𝐹 �1 − 𝛼𝛼2 , 2𝑋𝑋, 2(𝑁𝑁 − 𝑋𝑋 + 1)��
−1. 
 
 
 
2.9. General Conventions for Figures, Tables and Listings 
Analysis results will be presented using A4 sized sheets, and figures or summary tables will be 
described in portrait mode, whereas listings or lists of data in landscape mode in general. However, 
depending on specific requirements, any modification will be employed for each figure or table.   
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3. ANALYSIS 
3.1. Definitions of Population 
3.1.1. Full Analysis Set (FAS) 
FAS is defined as all enrolled subjects who have been administered at least one dose of the 
investigational product. However, subjects who had a major protocol violation (such as no consent 
or early registration before the trial) will be excluded. 
 
3.1.2. Per Protocol Set (PPS) 
The PPS will exclude all subjects in the FAS population who fail to satisfy major criteria of the 
protocol as follows:  
 Inclusion criteria  
 Exclusion criteria  
 Prohibited concomitant drug criteria  
 Prohibited concomitant therapy criteria 
 
3.1.3. Safety Analysis Set (SAF) 
Safety analyses will be performed on the SAF population subjects who are enrolled in the trial and 
who have received the assigned investigational product at least once for each treatment group. 
 
3.2. Analysis Principles  
The primary analysis for all efficacy endpoints will be performed on the FAS while the analyses on 
the PPS will be treated as reference data. Safety analyses will be performed on the SAF. 
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4. POPULATIONS AND GENERAL ANALYSIS PLAN  
4.1. Summary Data of Subjects 
Data for the following population will be summarized with the frequencies and the incidence rates. 
The data will be presented in figures or tables. 
 Subjects enrolled by the centralized registration system 
 SAS 
 Subjects who have not been administered the investigational product 
 FAS 
 Subjects who have provided informed consent 
 Subjects who were enrolled in the trial outside the trial period 
 PPS 
 Subjects in violation of inclusion criteria 
 Subjects in violation of exclusion criteria 
 Subjects in violation of prohibited concomitant drug usage 
 Subjects in violation of prohibited concomitant therapy  
 Subjects of withdrawal or discontinuation 
 
4.2. Handling of Subjects of Withdrawal and Discontinuation  
 
The frequencies and the proportion of all subjects of withdrawal or discontinuation will be 
summarized by assigned treatment group and will be presented according to reasons of withdrawal 
and discontinuation from the study. A listing will be created for all relevant cases, which will contain 
the following items. 
 Subject identification code 
 Number of days between enrollment and withdrawal 
 Primary reason for withdrawal 
 
All cases of deviation will be classified by reasons for deviation and treatment group. The 
frequency and proportion of each deviation will be analyzed. In addition, a listing will be created for 
all relevant cases, which will contain the following items: 
 Subject identification code 
 Number of days between enrollment and deviation 
 Deviation code name 
 Deviation description 
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4.3. Data Sets for Analysis   
A listing will be created for the excluded subjects in each analysis set, and will contain the 
following items: 
 Subject identification code 
 Inclusion or exclusion in each analysis set (FAS, PPS, and SAF) 
 
 
4.4. Investigational Product Adherence Status       
The SAF will be classified by treatment group and analyzed by frequency and proportion of 
investigational product adherence, and the following items will be included; 
 
 Total dose：Descriptive statistics of administered vials of the investigational product 
 Proportion of administration (dose taken/dose prescribed by investigators): descriptive 
statistics 
 Temporary drug cessation: no or yes (if yes, proportion will be presented in a listing.) 
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5. DEMOGRAPHIC AND BASELINE CHARACTERISTICS 
Demographic and other baseline characteristics will be summarized according to assigned treatment 
groups with descriptive statistics. Continuous variables will be summarized with demographic 
statistics (number of patients [n], mean, standard deviation, minimum, maximum, and median). 
Categorical variables will be summarized by frequencies and proportion according to assigned 
treatment groups. A t-test or Wilcoxon’s rank-sum test will be used for comparison of treatment 
group with continuous variables. Fisher’s exact test will be used with categorical data. 
Results from all analyses will be assessed against the significance level (α) of 0.05 at two-sided test.  
The following baseline demographics and clinical characteristics will be presented with nominal 
variables, ordinal variables, and continuous variables: 
 
Subject background 
 Nominal variables 
Gender, complications, medical history (e.g. GBS, diabetes), current and concomitant medications, 
date of onset of weakness, and antecedent infection 
 
 Ordinal variables 
Not applicable 
 
 Continuous variables 
Age, weight, height, 
 
Baseline data 
 Nominal variables 
- Urine test (urinary protein, urinary glucose) 
- Pregnancy test result 
- ECG results 
 
 Ordinal variables 
-FG, R-ODS score, ONLS score, MMT scale score 
 
 Continuous variables 
-Grip strength 
- Nerve Conduction Study: median and ulnar nerve conduction test parameters from baseline 
(CMAP amplitude, distal latency, motor nerve conduction velocity, F wave latency , SNAP 
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amplitude, sensory nerve conduction velocity) 
- Vital capacity and % vital capacity 
- Systolic and diastolic BP, temperature, and HR. 
 - Blood count: RBC, Hb, Hct, WBC, white blood cell differentiation (neutrophils, lymphocyte, 
monocyte, eosinophil, basophil), PLT 
- Chemistry panel: Total protein, albumin, urea nitrogen, creatinine, AST, ALT, γ-GTP, ALP, 
LDH, total bilirubin, glucose, Na, K, Cl, IgA, IgG, IgM, antiganglioside antibody 
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6. EFFICACY ANALYSIS  
 
6.1. Analysis Plan for Primary Endpoints 
The primary efficacy endpoint is the proportion of subjects who reach a score of FG2 or lower on the 
Hughes Functional Grading Scale at Week 4 (response rate).  
The primary safety endpoint is the expressed frequency and severity of any incidence of AE/SAEs 
after treatment with the investigational product. 
 
The main purpose of this study is to assess the response rate of FG= <2 at week 4. 
The sample size will be determined by the epidemiological data analysis of patients treated with 
IVIg at Chiba University Hospital. As H0 (null hypothesis) we assumed that a 4-week response 
threshold will be 50%, whereas in H1 (alternative hypothesis), we assumed the expected response 
rate to be more than 80%. The exact 90% confidence interval will be calculated by binomial 
distribution for the response rate of each assigned treatment group. For primary analysis, group 
comparison will not be performed between the eculizumab group and the placebo group. A 95% 
confidence interval will be provided as well. 
 
6.2. Analysis Plan for Secondary Endpoints   
The analyses of the secondary efficacy endpoints will be performed to support the discussion of the 
results of the primary analysis in this trial. A multiplicity adjustment will not be performed in this 
trial in assessing the secondary endpoints. 
 
6.2.1. Secondary Efficacy Endpoints 
(1) Proportion of subjects with improvement of one or more scores on the Functional Grading 
Scale at each visit from baseline and the changes 
 
The frequency and percentage of patients who improve by one or more grade at each visit 
(Baseline [Day1], Day29, Day 169 or Early Termination visit) will be summarized. FG score 
improvement at each visit（Baseline [Day 1], Day 29, Day 169 or Early Termination visit）from 
baseline will be described by the generalized linear mixed model (GLMM) (Breslow NE, 
Clayton DG, J Am Stat Assoc 1993;88(421): 9-25、Wolfinger RD, O'Connell MA, J Stat 
Comput Sim 1993; 48: 233-243.), to obtain point estimates and 95% confidence intervals. 
Correlation Structure is assumed unstructured, and Toeplitz, Autoregressive, or 
Compound-symmetry structure will be used in order if convergence is not obtained. 
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(2) Proportion of subjects who are able to walk unaided (FG2 or lower) at each visit  
The frequency and percentage of patients who are able to walk unaided (FG2 or lower) at each 
visit (Baseline [Day 1], Day 29, Day 169 or Early Termination visit) will be summarized. 
FG shifts from the baseline will be described by the GLMM, to obtain point estimates and 95% 
confidence limits. 
Correlation Structure is assumed unstructured, and Toeplitz, Autoregressive, or 
Compound-symmetry structure will be used in order if convergence is not obtained. 
 
(3) Duration required for improvement by at least one grade on the Functional Grading Scale 
(number of days) 
Days required for improvement by at least one grade will be defined as an event and the 
survival-time analysis will be performed according to the the Kaplan-Meier model. Cases other 
than event occurrences will be defined as censored cases and descriptive statistics values（event 
cases, censored cases, the point at which the cumulative event rate becomes 50% and its 95% 
confidence interval）. In order to compare groups, a log-rank analysis will be performed. The 
Cox Proportional-Hazards model will be used for the eculizumab adjusted hazard ratio to 
placebo group and two-sided 95% confidence interval. Allocation factors (FG, age) will be 
employed as adjustment factors. A 5% significance level will be employed for a two-sided test.  
 
(4) Proportion of subjects who reach FG1 or 0 at Week 24 
The frequency and percentage of subjects who have reached FG0 or FG1 at Week 24 (Day 169) 
will be summarized according to each assigned group. 
The response rate will be calculated from binomial distribution with a 95% of confidence 
interval for each assigned treatment group. Fisher’s exact method will be used for group 
comparison. A 5% significance level will be used for a two-sided test. 
 
(5) Change in FG score at each visit in comparison with the peak disability score  
The descriptive statistic values (n, mean, standard deviation, minimum, maximum, and median) 
will be calculated for changes in the FG score at each visit (Day 29, Day 169, or early 
termination visit) compared to peak disability FG score at baseline. 
 
 
(6) Proportion of subjects with clinically relevant improvements in the R-ODS score - those 
who show an increase in the R-ODS score (0-48) converted to the centile metric score 
(0-100) by at least six points at each visit - 
Changes in R-ODS score between the baseline and each visit (Day 29, Day 169, early 
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termination visit) will be calculated. The frequency and proportion will be calculated for 
subjects who show an increase of at least 6 points in the R-ODS score, converted to the centile 
metric score.  
A 95% confidence interval will be calculated by binomial distribution to evaluate whether or 
not there is a 6 point increase in the converted centile metric score in each assigned treatment 
group. 
 
(7) Proportion of subjects with a clinically relevant improvement in ONLS (a decrease in the 
ONLS score from baseline by at least 1 point) at each visit 
Change in ONLS score from baseline at each visit (Day 29, Day169, early termination visit) 
will be calculated. Frequency and percentage will be summarized for subjects whose score 
decrease is at least one point). Absence or presence of changes with more than one point will be 
summarized. Two-sided 95% of confidence interval will be calculated by binomial distribution 
to evaluate whether or not there is a change of more than one point in each assigned treatment 
group. 
 
(8) Proportion and frequency of subjects who require ventilatory support (FG 5) 
The frequency and percentage of patients who require ventilatory support from the start of the 
investigational product administration to the end of the trial, will be summarized.. Two-sided 
95% of confidence interval will be calculated by binomial distribution for presence/absence of 
cases who require ventilatory support by each assigned treatment group. 
 
(9) Duration of ventilatory support due to GBS 
A survival-time analysis will be performed according to the Kaplan-Meier Model for the 
number of days required for ventilatory support, defined as an event. Cases outside of event 
occurrences will be defined as censored cases and descriptive statistical values（event cases, 
censored cases, the point at which the cumulative event rate becomes 50% and its 95% 
confidence interval）will be obtained. In order to compare groups, a log-rank analysis will be 
performed with two-sided 5% significance level. However, for the cases whose reasons for 
termination of ventilatory support are death, competitive risk model (Fine JP, Gray RJ J Am 
Stat Assoc 1999;94(446): 496 – 509.)will be used for estimation of cumulative events 
percentage. 
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(10) Occurrence of relapse between the IP administration period and the end of the post IP 
period 
A survival analysis will be performed for the number of days of relapse occurrence based on the 
Kaplan-Meier model. Cases other than event occurrences will be defined as censored cases and 
descriptive statistics values (event cases, censored cases, the point at which the cumulative 
event rate becomes 50% and its 95% confidence interval ) will be obtained. A log-rank test will 
be performed for group comparison. 
The Cox Proportional-Hazards Model will be used to estimate the adjusted hazard ratio of the 
eculizumab group against the placebo group, and the two-sided 95% confidence interval. 
Covariates as adjustment factors will be allocation factors (FG, age).  
 
(11) Overall survival from the start of the IP administration until the end of enrollment (OS) 
A survival analysis will be performed for the number of days until occurrence of death based on 
the Kaplan-Meier model. Cases other than event occurrences will be defined as censored cases 
and descriptive statistical values (event cases, censored cases, the point at which the cumulative 
event rate becomes 50% and its 95% confidence interval) will be presented. A log-rank test will 
be performed for group comparison. 
The Cox Proportional-Hazards Model will be used to estimate the adjusted hazard ratio of the 
eculizumab group against the placebo group, and the two-sided 95% confidence interval. 
Covariates as adjustment factors will be allocation factors (FG, age).  
 
(12) Change in grip strength at each visit from baseline 
The change in the rate of results in grip strength from baseline at each visit (Day 29, Day 169, 
or Early termination visit) will be calculated for descriptive statistical values (n, mean, standard 
deviation, minimum, maximum, and median). 
 
(13) Change in results of the manual muscle test (MMT score) at each visit from baseline 
Change in the rate and results of the manual muscle test (MMT) scores from baseline at each 
visit (Day 29, Day 169, or early termination visit) for boths sides of the following thirteen 
areas: deltoid muscle, biceps brachii, wrist extension, iliopsoas muscle, quadriceps muscle, and 
tibialis anterior muscle and neck anteflexion. The results will be calcluated for descriptive 
statistic values (n, mean, standard deviation, minimum, maximum, and median). 
In addition, the total MMT scores for all muscles will be calcuated for change in the rate and 
results from baseline at each visit (Day 29, Day 169, or early termination visit) for descriptive 
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statistic values (n, mean, standard deviation, minimum, maximum, and median). 
 
(14) Change in the rate and results of ulnar nerve conduction test parameters (CMAP 
amplitude, distal latency, motor nerve conduction velocity, F-wave latency, SNAP 
amplitude, sensory nerve conduction velocity) between baseline and visits 
 
Change in the rate and results of median and ulnar nerve conduction test parameters (CMAP 
amplitude, distal latency, motor nerve conduction velocity, F-wave latency, SNAP amplitude, 
sensory nerve conduction velocity) from baseline at each visit (Day 29, Day 169, or early 
termination visit) will be calcuated for descriptive statistic values (n, mean, standard deviation, 
minimum, maximum, and median). 
 
(15) Change in vital capacity and % vital capacity at each visit from baseline 
The descriptive statistic values (n, mean, standard deviation, minimum, maximum, and median) 
will be calcuated for changes in the rate and results of vital capacity and % vital capacity from 
baseline at each visit (Day 29, Day 169, or early termination visit)  
 
 
(16) Proportion of patients who undergo re-administration of IVIg 
Data on the frequency and the incidence rate will be collected for subjects who have been 
readministered with IVIg from the start of IP administration until the end of enrollment. 
Presence or absence of IVIg re-administration will be presented from binomial distribution with 
accurate two-sided 95% CI. Fisher’s exact test will be used for treatment comparison against 
the significance level (α) of 0.05 at a two-sided test. 
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7.  SAFETY ANALYSIS 
 
7.1. Analysis Plan of Adverse Events  
 
7.1.1 Incidence rate of adverse events 
 
Adverse events will be classified according to MedDRA/J terminology. All adverse events will be 
summarized by whether or not events have occurred, the severity grade, and the number of subjects 
and the incidence rate of subjects, and by treatment group. A listing will be also provided.  
Presence or absence of subjects will be presented from binomial distribution with 95% confidence 
interval. Fisher’s Exact Test will be used for treatment comparison against the significance level (α) 
of 0.05 at a two-sided test. 
The number of occurrences which may include multiple occurrences of the same AE in one 
patient will be summarized and analyzed in a listing as described above. 
 
7.1.2 Incidence rate of serious adverse events (SAEs) 
 
7.1.1.  
Serious adverse events will be classified according to MedDRA/J terminology. All serious adverse 
events will be summarized by presence or absence of subjects in whom the events occurred, severity 
grade, and the number of subjects/the percentage of subjects, and by treatment group. A listing will 
be also produced  
Presence or absence of subject will be presented from binomial distribution with 95% confidence 
interval. Fisher’s exact test will be used for treatment comparison against the significance level (α) 
of 0.05 at a two-sided test. 
Likewise, the number of occurrences which may include multiple occurrences of the same SAE in 
one patient will be summarized and analyzed in a listing as described above. 
 
7.1.3 Incidence rate of adverse events whose causal relationship cannot be denied 
7.1.2.  
Adverse events whose causal relationship cannot be denied will be classified according to  
MedDRA/J terminology. A listing will be produced for presence or absence of adverse 
events, the number of subjects, the percentage of subjects, and by each treatment group. 
Presence or absence of subjects will be presented from binomial distribution with 95% 
confidence interval. Fisher’s exact test will be used for treatment comparison against 
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the significance level (α) of 0.05 at a two-sided test. 
Likewise, the number of occurrences which may include multiple occurrences of the 
same event in one patient will be summarized and analyzed in a listing as described 
above. 
 
7.2. Analysis Plan for Clinical Assessment Values and Vital Signs  
Changes in measurement values such as clinical laboratory test values and vital signs will be 
analyzed. Each measurement parameter will be calculated for descriptive statistic values (n, mean, 
standard deviation, minimum, maximum, and median) and interval estimation for the parent 
population. For urinalysis parameters, the frequency and the incidence rate will be calculated by 
two-sided 95% CI. For each measurement parameter (except for urinalyses), trajectories of the 
average values by treatment group will be described in a figure. The description of assessments is 
described below.   
 
Clinical Laboratory 
Test 
Measurement Parameters Measurement timing 
Hematological Test 
RBC, Hb, Hct, WBC, WBC differentiation 
[neutrophils, lymphocyte, monocyte, essinophil, 
basophil], PLT 
At the time of screening、 
Day 8, Day 15, Day 22, Day 29, 
Day 43, Day 57, Day 85, Day 113, 
Day 169, early termination visit, 
follow-up visit 
Chemistry Panel 
Total protein, albumin, urea nitrogen, creatinine, 
AST, ALT, γ-GTP, ALP, LDH, total bilirubin, 
glucose (随時), Na, K, Cl, IgA, IgG, IgM 
At the time of screening、 
Day 8, Day 15, Day 22, Day 29, 
Day 43, Day 57, Day 85, Day 113, 
Day 169, early termination visit, 
follow-up visit 
Urinalysis Urinary protein, urinary glucose, hematuria 
At the time of screening、 
Day 8, Day 15, Day 22, Day 29, 
Day 43, Day 57, Day 85, Day 113, 
Day 169, early termination visit, 
follow-up visit 
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Vital signs 
Blood pressure [systolic/diastolic] , 
HR, temperature 
At the time of screening、 
Day 8,Day 15,Day22,Day 29, 
Day43,Day 57,Day 85,Day 113, 
Day 169,Early termination visit, 
Follow-up visit 
 
8. ANALYSES OF OTHER PARAMETERS  
Analyses of changes on the following measurement parameters will be performed. Listings will be 
provided for some specific variables accordingly. In regards with other variables, nominal variables 
or ordinal variables will be collected for frequencies, incidence rates and interval estimation, 
whereas continuous variables will be calculated for descriptive statistic values (n, mean, standard 
deviation, minimum, maximum, and median) and interval estimation for parent population. Interval 
estimation will be calculated by binominal distribution with an accurate confidence interval. A 95% 
CI will be provided at a two-sided test. The assessment description is indicated below. 
 
Exams Parameters Timing Analysis 
Antiganglioside 
antibodies 
Antibodies of GM1, GD1a, 
GalNAc-GD1a, GQ1b, and their 
ganglioside complexes 
Day 0 or before 
investigational 
product 
administration on 
Day 1  
Continuous 
variables 
Eculizumab 
concentration in 
serum 
Eculizumab concentration in serum 
Day 1, Day 8,  
Day 29, Day 43 
Continuous 
variables 
Hemolytic 
complement 
activity in serum 
Hemolytic complement activity in serum 
Day 1, Day 8,  
Day 29, Day 43 
Continuous 
variables 
Immunoglobulin 
(IVIg) 
Administration period, dose, decrease (if 
yes, specify the reason), termination 
(if yes, specify the reason) 
– Listing 
Concomitant 
medication 
Drug name, administration period, dose, 
dosing method, reasons for administration 
– Listing  
Concomitant 
treatment 
Treatment, treatment period, reasons for 
treatment 
– 
Listing 
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9. SUBGROUP ANALYSIS Plan for Subgroup Analysis 
Subgroup analysis for “6. Efficacy Analysis” or “7. Safety Analysis ” will be performed 
depending on GBS subtypes defined by the presence of antiganglioside antibodies 
(Antibodies of GM1, GD1a, GalNAc-GD1a, GQ1b, and their ganglioside complexes). 
  
10. REVISION HISTORY 
10.1. Changes According to Protocol Amendment 
Date Name Distribution Changes 
- - - - 
 
10.2. Revision History of Statistical Analysis Plan 
Date Name Distribution Changes 
2015/June/20 Kazue Nagai None Version 0  
    
    
 
11. STATISTICAL ANALYSIS IMPLEMENTATION SYSTEM 
 
11.1. Statistical Analysis Supervisor 
Chiba University Graduate School of Medicine, Department of Global Clinical Trials   
Yasunori Sato, PhD 
 
11.2. Statistical Analyses 
Chiba University Graduate School of Medicine, Department of Global Clinical Trials 
Kengo Nagashima, PhD 
 
Chiba University Hospital, Clinical Research Center 
Kazue Nagai, PhD 
 
11.3. Hardware System 
The following hardware version will be used for statistical analysis. 
 Microsoft Windows XP or following OS 
 
11.4. Software System 
The following software will be used for statistical analysis. 
 SAS 9.4 or higher  
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 Microsoft Office 2013or after 
 Adobe Acrobat XI or higher 
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12. Approval 
This statistical analysis plan for “A PROSPECTIVE, MULTI-CENTER, PHASE II STUDY TO 
EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH 
GUILLAIN–BARRÉ SYNDROME” was approved and fixed prior to the final data analysis.  
 
 
                                        23/June/2015 
                                            Satoshi Kuwabara 
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